## Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients

Franco Casamassima<sup>1</sup>, Laura Masi<sup>1</sup>, Claudia Menichelli<sup>1</sup>, Ivano Bonucci<sup>1</sup>, Emanuele Casamassima<sup>2</sup>, Massimo Lazzeri<sup>3</sup>, Massimo Gulisano<sup>4</sup>, and Stefano Aterini<sup>4,5</sup>

<sup>1</sup>Clinical Radiobiological Institute, University of Firenze, Firenze; <sup>2</sup>Institute Ricerche Cliniche Fanfani, Firenze; <sup>3</sup>Department of Urology, Santa Chiara Hospital, Firenze; <sup>4</sup>Department of Anatomy, Histology and Forensic Medicine, University of Firenze, Firenze; <sup>5</sup>Misericordia e Dolce Hospital, Prato, Italy

## ABSTRACT

Aims and background. In patients with recurrent prostate cancer, discriminating local or systemic recurrence is critical to decide second-line treatment. We investigated the capability of stereotactic body radiotherapy to treat limited nodal recurrences, detected using choline PET scan.

**Methods and study design.** Seventy-one patients with biochemical failure were studied after prostate cancer treatment: prostatectomy (28), radiotherapy (15) or both (28). Following computed tomography and choline PET imaging, stereotactic body radiotherapy was delivered on pathological lymphatic areas by 6 MV Linac, using dynamic micromultileaf collimation and intensity-modulated arc therapy optimization. Sixty days post-treatment, choline PET/CT imaging was carried out.

**Results.** Median follow-up was 29 months (range, 14.4-48). Choline PET detected recurrences in 39 of 71 patients. Median PSA velocity was 0.40 ng/ml/year in PET-negative patients and 2.88 ng/ml/year in PET-positive subjects (P < 0.05). Twenty-five patients with limited nodal recurrences, out of the 71 submitted to choline PET, received eradicative radiotherapy. Persistent regression was recorded in 13; early spread to bone was found in 2 cases; lymph node recurrences in 8, all in sites outside the irradiated areas; 2 patients were lost to follow-up. At the 3-year follow-up, overall survival, disease-free survival and local control rates were 92%, 17% and 90%, respectively. In patients with a complete regression, PSA fell from 5.65 to 1.40 ng/ml (median). PSA nadir value (median 1.06 ng/ml) was maintained for 5.6 months (median).

**Conclusions.** Stereotactic body radiotherapy was effective in disease eradication of limited nodal recurrences from prostate cancer, saving patients from, or at least postponing, systemic treatments. Free full text available at www.tumorionline.it

*Key words:* choline-PET, nodal relapses, prostate cancer, salvage stereotactic body radiotherapy.

Correspondence to: Prof Franco Casamassima, UO di Radiobiologia Clinica, Piazza Indipendenza 14, 50129 Firenze, Italy. Tel +039-055-50381; fax +039-055-480676; e-mail f.casamassima@dfc.unifi.it

Received March 31, 2010; accepted October 29, 2010.